TLR9 and neoplasm: In a murine model of ovarian cancer, immunization with microparticles containing ligands of TLR9 and nucleotide‐binding oligomerization domain 2 leads to the accumulation of T cells in the tumours and prolongs the survival of tumour‐bearing mice.